MSCI
RPRX

Henry A. Fernandez

Known title: DirectorCIK: 0001416750

Henry A. Fernandez's purchase track record

How the stock did after each of Henry A. Fernandez's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
7
of 8 since February 24, 2022
Stock higher 6 months later
86%
3 months: 63%
Median 6-month return
+9.5%
3 months: +3.7%
Beat the S&P 500
57%
median +0.9% vs. index
PurchaseStockAmount3 months6 months
5/15/2026MSCI$2.25M+1.3%pending
2/13/2026MSCI$3.56M+7.2%+8.6%
12/5/2025MSCI$6.70M+6.2%+15.2%
7/24/2025MSCI$6.73M-0.5%+9.5%
2/24/2025MSCI$3.04M-0.9%+0.7%
12/5/2024MSCI$1.78M-6.9%-6.9%
4/25/2024MSCI$6.06M+16.3%+27.9%
2/24/2022RPRX$1.22M+6.1%+16.3%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

MSCI to Update Index Rules, May Exclude Bitcoin Treasury Stocks. MSCI is preparing to roll out new index standards that could remove certain Bitcoin treasury and strategy stocks from its indices. The changes aim to tighten eligibility criteria and may reduce exposure for those holdings. The move could affect MSCI’s index offerings and the visibility of the affected stocks.

this person other insiders at MSCI

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.

this person other insiders at RPRX

Transaction History

MSCI▲ Buy$67K
MSCI▲ Buy$134K
MSCI▲ Buy$695K
MSCI▲ Buy$631K
MSCI▲ Buy$451K
MSCI▲ Buy$226K
MSCI▲ Buy$45K
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▲ Buy$124K
MSCI▲ Buy$187K
MSCI▲ Buy$104K
MSCI▲ Buy$3.1M
MSCI▲ Buy$192K
MSCI▲ Buy$558K
MSCI▲ Buy$1.7M
MSCI▲ Buy$1.0M
MSCI▲ Buy$272K
MSCI▲ Buy$597K
MSCI▲ Buy$259K
MSCI▲ Buy$43K
MSCI▲ Buy$75K
MSCI▲ Buy$139K
MSCI▲ Buy$293K
MSCI▲ Buy$232K
MSCI▲ Buy$599K
MSCI▲ Buy$296K
MSCI▲ Buy$170K
MSCI▲ Buy$43K
MSCI▲ Buy$61K
MSCI▲ Buy$130K
MSCI▲ Buy$22K
MSCI▲ Buy$13K
MSCI▲ Buy$24K
MSCI▲ Buy$10K
MSCI▲ Buy$1.3M
MSCI▲ Buy$5.4M
RPRX▲ Buy$37K
RPRX▲ Buy$0
RPRX▲ Buy$37K
MSCI▲ Buy$2.7M
MSCI▲ Buy$58K
MSCI▲ Buy$285K
MSCI▲ Buy$0
MSCI▼ Sell$19.0M
RPRX▲ Buy$37K
MSCI▲ Buy$303K
MSCI▲ Buy$1.1M
MSCI▲ Buy$366K
RPRX▲ Buy$37K
RPRX▲ Buy$37K
RPRX▲ Buy$0
MSCI▲ Buy$462K
MSCI▲ Buy$400K
MSCI▲ Buy$743K
MSCI▲ Buy$354K
MSCI▲ Buy$417K
MSCI▲ Buy$2.0M
MSCI▲ Buy$772K
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▲ Buy$230K
MSCI▲ Buy$667K
RPRX▲ Buy$37K
MSCI▼ Sell$2.4M
MSCI▲ Buy$0
MSCI▲ Buy$0
MSCI▼ Sell$27.1M
RPRX▲ Buy$37K
RPRX▲ Buy$37K
RPRX▲ Buy$37K
RPRX▲ Buy$0
RPRX▲ Buy$37K
MSCI▼ Sell$8.8M
MSCI▲ Buy$0
RPRX▲ Buy$37K
RPRX▲ Buy$37K
RPRX▲ Buy$37K
RPRX▲ Buy$0
RPRX▲ Buy$37K
RPRX▲ Buy$1.2M
MSCI▲ Buy$0
MSCI▼ Sell$23.4M
RPRX▲ Buy$37K
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▼ Sell$0
MSCI▼ Sell$0
RPRX▲ Buy$37K

We use analytics to understand how market-wall is used. No personal data is sold.